Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A 23-year-old with high estrogen levels is considering starting finasteride for hair loss and plans to use a low dose topical treatment while also seeking to lower estrogen levels. They will consult an endocrinologist for further guidance.

Excessive scalp sebum, worsened by DHT, can lead to inflammation and hair loss, with clascoterone mentioned as a treatment. Diet changes seem ineffective for scalp sebum, and treatments like minoxidil and finasteride are suggested.

A 24-year-old woman being diagnosed with androgenic alopecia (AGA) who is scared and confused about her hair loss, and the treatment options of Minoxidil, finasteride, RU58841, spironolactone, and possibly a biopsy.

The user is using 0.5mg dutasteride and 2.5mg minoxidil for hair loss and is considering additional treatments like microneedling and RU58841. They feel discouraged due to lack of progress on the crown/mid scalp but are advised to be patient and consistent, as improvements can take up to a year.

Clascoterone's full trial results are expected by mid-July 2026, but skepticism exists about timely release. Clascoterone is available at 5% from some telehealth companies.

The user had a hair transplant 5 years ago and is currently using 1 mg finasteride and topical minoxidil but is not seeing an increase in hair volume. They are considering another transplant to improve hair volume.

The conversation discusses various treatments for hair loss, including high doses of dutasteride, oral minoxidil, RU58841, microneedling, ketoconazole shampoo, and other supplements like pumpkin seed oil and multivitamins. It also touches on more extreme measures like estrogen therapy and castration, with some users emphasizing the importance of overall health and nutrition.

The user has high DHT levels despite using dutasteride, which may not be effective due to potential damage or spoilage. They are considering a hair transplant if DHT levels don't decrease after two years.

Breezula's effectiveness is uncertain, with some users skeptical about its potential and others noting its recent availability on the grey market. A user reported success with a stack of Dutasteride (oral), Minoxidil (topical), and RU58841 (topical), achieving significant hair improvement after 18 months.

New hair loss treatments like VDPHL01, PP405, Gt20029, and Breezula are anticipated, with VDPHL01 possibly releasing in 2027/28. Current treatments include finasteride, dutasteride, and minoxidil, but new options are eagerly awaited.

The conversation discusses using oral spironolactone for hair loss in males when 5ari blockers fail. Concerns are raised about spironolactone's side effects, and alternatives like pyrilutamide and breezula are suggested.

A 20-year-old male experiencing hair loss is using topical finasteride and recently added dutasteride but is still losing hair and considering giving up. Suggestions include being patient, giving dutasteride more time, trying oral finasteride, adding minoxidil, and considering other treatments like low-level laser therapy.

A user shared their 1 year and 5 months update on using finasteride and minoxidil for hair loss, noting improved hair density but a still receding hairline. They mentioned being inconsistent with minoxidil initially and experiencing more hair shedding after starting it.

The conversation is about a user's progress with hair regrowth after using minoxidil for three months. Many suggest adding finasteride to maintain results, and the user also uses ketoconazole shampoo for dandruff.

The user has been experiencing continuous hair loss despite using finasteride, minoxidil, and dermastamping. They are seeking advice on what to do next.

DHT, not testosterone, causes hair loss. Treatments like finasteride, dutasteride, and RU58841 target DHT to manage hair loss.

The conversation is about finding a source for RU58841 in Canada as an additional treatment for hair loss, alongside oral minoxidil and dutasteride. Alternatives like kx826 are suggested, with some users discussing prices and sources for these products.

RU58841 5% is theoretically equivalent to 2mg of dutasteride for hair loss treatment, with RU58841 offering higher potential but more variability due to absorption issues. Users discuss the effectiveness of RU58841 and dutasteride, with some preferring dutasteride for consistent results and others finding success with RU58841.

The conversation discusses using RU58841 with primobolan or masteron to protect hair while on steroids, alongside dutasteride. Users suggest caution with these compounds due to potential hair loss and discuss alternatives like nandrolone and EQ for better hair safety.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

The user switched from finasteride to 1mg dutasteride daily due to continued hair loss and is also using minoxidil and rosemary oil. They are seeking advice on whether to increase the dutasteride dosage for better regrowth.

Switching from finasteride to dutasteride can cause initial shedding, but many see long-term hair regrowth and stabilization. Responses vary, with some experiencing fewer side effects and others finding it less effective.

Dutasteride at 0.5mg has not cleared acne and has caused arm hair thickening. The user plans to increase the dose to 1mg.

Hair loss can be caused by various factors such as stress, thyroid issues, and genetics. Treatments mentioned include dutasteride, DHT blockers, and thyroid medication, though results vary.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

PP405 is ineffective for miniaturized, fibrosed hair follicles in androgenetic alopecia. AMP303 may activate hair follicle stem cells, but minoxidil and finasteride are still the main treatments.

PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.

Young people are using hair loss treatments like finasteride and dutasteride without having hair loss, influenced by social media trends. Concerns are raised about the potential long-term effects of taking these medications at a young age.

Testosterone can still cause hair loss even when DHT is blocked by dutasteride, especially if hair follicles are sensitive. Topical treatments like RU58841 or pyrilutamide may help, but their long-term effectiveness is uncertain compared to dutasteride.